XSHE
300534
Market cap330mUSD
Jul 10, Last price
7.50CNY
1D
1.49%
1Q
-21.71%
Jan 2017
-58.86%
IPO
21.53%
Name
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd operates as a pharmaceutical enterprise, focusing on the research, development, manufacturing, and commercialization of traditional Chinese medicines, health supplements, and active pharmaceutical ingredients (APIs). Its extensive product line includes therapeutic remedies such as Yuanhu Analgesic dropping pills, Qiwei Wenyang capsules, Maxing cough capsules, Shuxinning tablets, Panax notoginseng pills, Anti-inflammatory and gallbladder tablets, Children's Qingfei cough tablets, Pediatric Qinggan tablets, Suanzaoren oil dropping pills, Xiaoshuan Tongluo tablets, Xiaoyanlidan tablets, Compound Danshen tablets, Astragalus Angelica capsules, and berberine tannin films. Beyond its core manufacturing, the company is actively involved in the cultivation, procurement, processing, and distribution of Chinese medicinal raw materials. Its operations further encompass project investment and management, alongside the import, sale, logistics, and export of pharmaceutical goods. Established in 2002, Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd is headquartered in Lanzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||